William Proctor Harris

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 995 citations · Full text

Gastrointestinal Oncology, Medicine, Biliary Cancer +8

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa et al. · Journal of Clinical Oncology · 2020 · 601 citations

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 467 citations

Nanotherapeutics, Pathology, Phase Ii Study +17

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation

Andrew X. Zhu, Teresa Macarulla, Milind Javle et al. · JAMA Oncology · 2021 · 436 citations · Full text

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley, Bruno Sangro, William Proctor Harris et al. · Journal of Clinical Oncology · 2021 · 427 citations · Full text